JPRN-UMIN000006855已完成未知
the efficacy for type 2 Diabetes of Repaglinide taking twice or three times a day - Repaglinide:twice or three times a day
Graduate School of Medicine, Yokohama City University0 个研究点目标入组 40 人开始时间: 2011年12月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.type 1 diabetes 2.severe liver dysfunction 3.severe renal dysfunction
研究者
相似试验
已完成
不适用
Efficacy and safety of repaglinide on glycemic control in diabetic patients with chronic renal failure [Diamond study-2]Diabetic patients with chronic renal failureJPRN-UMIN000009166Diamond study group20
已完成
不适用
Add-on or switch to repaglinide for type 2 diabetes with sitagliptin: Randomized controlled open-labelled trial.type 2 diabetesJPRN-UMIN000011420Toho University Graduate School of Medicine.40
尚未招募
不适用
Effect of Dapagliflozin for type 2 diabetes mellitus with fatty liverJPRN-UMIN000026549Kagawa prefectural central hospital25
招募中
3 期
Role of Remogliflozin in patients with Type 2 Diabetes with Acute Heart FailureCTRI/2021/08/035354Glenmark Pharmaceuiticals
已完成
3 期
Double blind, randomised, comparative, multicentre, parallel-group study design to evaluate the effects of Pioglitazone on cardiovascular risk markers in type 2 diabetes mellitusACTRN12608000534381Takeda Italia Farmaceutici S.p.A.100